Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Comparison · United States
Zepbound vs Wegovy: cost, weight loss and how they differ
Zepbound produced more weight loss than Wegovy in the only head-to-head trial: an average of 20.2% of body weight against 13.7% after 72 weeks (SURMOUNT-5, 2025)[1]. At the starting dose, Wegovy costs less than Zepbound. Paying cash, Wegovy starts at $149 a month for the pill at NovoCare Pharmacy, checked November 19, 2026; Zepbound starts at $299 a month for the KwikPen at LillyDirect, checked November 19, 2026. Zepbound (tirzepatide) is a weekly injection only; Wegovy (semaglutide) comes as a weekly pen or a daily pill. Which suits you depends on your health, your coverage and your budget, and is a decision to make with a clinician.
Clinical facts checked against the FDA labels and the trial publications on November 5, 2026. Prices read from each seller's own page, last read November 19, 2026. Informational only, not medical advice.
Zepbound vs Wegovy at a glance
Active ingredient
Zepbound: Tirzepatide (Eli Lilly)[6]
Wegovy: Semaglutide (Novo Nordisk)[7]
How it works
Zepbound: Acts on two receptors: GIP and GLP-1[6]
Wegovy: Acts on one receptor: GLP-1[7]
FDA approval for weight management
Zepbound: November 8, 2023[8]
Wegovy: Injection June 4, 2021; pill December 22, 2025[9],[12]
Other FDA approved uses
Zepbound: Moderate to severe obstructive sleep apnea in adults with obesity (approved December 20, 2024)[10],[6]
Wegovy: Lowering the risk of major heart events in adults with heart disease and obesity or overweight (approved March 8, 2024); the injection also treats MASH, a liver disease, under accelerated approval[11],[7]
Who it is approved for
Zepbound: Adults[6]
Wegovy: Adults; the injection also for children aged 12 and older with obesity[7]
Form and schedule
Zepbound: Injection once a week: single-dose pen, KwikPen or vial. No pill[6]
Wegovy: Injection pen once a week, or a pill once a day[7]
Label dose range
Zepbound: Starts at 2.5 mg a week, raised in steps of at least 4 weeks; maintenance 5, 10 or 15 mg a week[6]
Wegovy: Pen: starts at 0.25 mg a week, maintenance 1.7 or 2.4 mg, up to 7.2 mg for some adults. Pill: starts at 1.5 mg a day, maintenance 25 mg[7]
Average weight loss, head to head
Zepbound: 20.2% at 72 weeks (SURMOUNT-5)[1]
Wegovy: 13.7% at 72 weeks (SURMOUNT-5)[1]
Average weight loss, own pivotal trial
Zepbound: 15.0%, 19.5% and 20.9% at 72 weeks on 5, 10 and 15 mg, against 3.1% on placebo (SURMOUNT-1)[2]
Wegovy: Pen 2.4 mg: 14.9% at 68 weeks, against 2.4% on placebo (STEP 1). Pill 25 mg: 13.6% at 64 weeks, against 2.2% (OASIS 4)[3],[4]
Boxed warning
Zepbound: Risk of thyroid C-cell tumors[6]
Wegovy: Risk of thyroid C-cell tumors[7]
Weight loss: what the trials found
SURMOUNT-5 is the only trial that has compared the two directly. It enrolled 751 adults with obesity and without type 2 diabetes and gave each the highest dose they could tolerate of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg), once a week for 72 weeks. Average weight loss was 20.2% on tirzepatide and 13.7% on semaglutide, and waist circumference fell by 18.4 cm against 13.0 cm. People on tirzepatide were more likely to lose at least 10%, 15%, 20% and 25% of their weight[1]. The trial was open-label (participants knew which medicine they took) and was funded by Eli Lilly, which makes Zepbound.
Each medicine was also tested against placebo in its own pivotal trial. On Zepbound, average weight loss at 72 weeks was 15.0%, 19.5% and 20.9% on 5, 10 and 15 mg, against 3.1% on placebo[2]. On the Wegovy pen at 2.4 mg it was 14.9% at 68 weeks, against 2.4% on placebo[3]. On the 25 mg Wegovy pill it was 13.6% at 64 weeks, against 2.2%[4]. A higher 7.2 mg Wegovy dose produced 18.7% at 72 weeks, against 15.6% on 2.4 mg and 3.9% on placebo[5].
Those placebo-controlled trials ran at different times, for different lengths and in different people, so their numbers are not a head-to-head comparison: only SURMOUNT-5 is. Every figure is an average, not a prediction for any one person.
Zepbound vs Wegovy cost without insurance
At the starting dose, Wegovy costs less than Zepbound. Wegovy starts at $149 a month for the pill at NovoCare Pharmacy, checked November 19, 2026. Zepbound starts at $299 a month for the KwikPen at LillyDirect, checked November 19, 2026. These are starting-dose medicine prices, read from each seller's own pricing page. The manufacturers' own pharmacies (LillyDirect for Zepbound, NovoCare Pharmacy for Wegovy) print no membership and need a prescription you already hold; the telehealth programs supply the clinician and the prescription and bill a membership on top. A prescription is decided by a licensed clinician and is never guaranteed.
The manufacturers' published list prices, which almost no one pays, are $1,086.37 for Zepbound (checked Nov 12, 2026) and $1,349.02 for Wegovy (checked Nov 19, 2026).
Zepbound cash prices
- LillyDirectManufacturer self-pay
$299/mo Zepbound KwikPenNo membership printed, pen needles sold separately, prescription required. Checked Nov 19, 2026.
- LillyDirectManufacturer self-pay
$299/mo Zepbound vialNo membership printed, needles and syringes sold separately, prescription required. Checked Nov 19, 2026.
$299/mo Zepbound KwikPenMembership $149/mo month to month, $39 the first month, billed separately. Checked Nov 19, 2026.
$299/mo Zepbound vialMembership $149/mo month to month, $39 the first month, billed separately. Checked Nov 19, 2026.
$299/mo Zepbound KwikPenMembership $149/mo month to month, $39 the first month, plan rates from $74/mo, billed separately. Checked Nov 19, 2026.
Wegovy cash prices
- NovoCare PharmacyManufacturer self-pay
$149/mo Wegovy pillNo membership printed, prescription required. Checked Nov 19, 2026.
$149/mo Wegovy pillMembership $149/mo month to month, $39 the first month, billed separately. Checked Nov 19, 2026.
$149/mo Wegovy pillMembership $149/mo month to month, $39 the first month, plan rates from $74/mo, billed separately. Checked Nov 19, 2026.
- NovoCare PharmacyManufacturer self-pay
$199/mo Wegovy penOffer is for 2 monthly fills through December 31, 2026; then $349 per monthNo membership printed, prescription required. Checked Nov 19, 2026.
$199/mo Wegovy penMembership $149/mo month to month, $39 the first month, billed separately. Checked Nov 19, 2026.
$199/mo Wegovy penLimited-time offer for first two months; then $349Membership $149/mo month to month, $39 the first month, plan rates from $74/mo, billed separately. Checked Nov 19, 2026.
Online programs that prescribe brand-name Zepbound and Wegovy, from our price archive. Each runs its own clinician review, and its membership is billed separately.
For one medicine at a time, with every seller and its price history, see Zepbound cost without insurance and Wegovy cost without insurance, or the brand-name GLP-1 price chart.
Price by dose: what the manufacturers print
Both medicines are started at a low dose and raised, and the cash price rises with the dose. This is each manufacturer's own wording from its self-pay page, quoted as we read it. Your dose is set by your prescriber.
Zepbound KwikPen, LillyDirect, read Nov 19, 2026
“2.5 mg/0.6 mL (starting dosage) $299/month, 5 mg/0.6 mL $399/month, 7.5 mg/0.6 mL $449/month when you refill within 45 days, 10 mg/0.6 mL $449/month when you refill within 45 days, 12.5 mg/0.6 mL $449/month when you refill within 45 days, 15 mg/0.6 mL $449/month when you refill within 45 days. Regular prices will apply if prescription is not refilled within 45 days ($499 for 7.5mg, $699 for 10mg, $699 for 12.5mg, and $699 for 15mg).”
Zepbound vial, LillyDirect, read Nov 19, 2026
“2.5 mg/0.5 mL (starting dosage) $299/month, 5 mg/0.5 mL $399/month, 7.5 mg/0.5 mL $449/month when you refill within 45 days, 10 mg/0.5 mL $449/month when you refill within 45 days, 12.5 mg/0.5 mL $449/month when you refill within 45 days, 15 mg/0.5 mL $449/month when you refill within 45 days. Regular prices will apply if prescription is not refilled within 45 days ($499 for 7.5mg, $699 for 10mg, $699 for 12.5mg, and $699 for 15mg).”
Wegovy pill, NovoCare Pharmacy, read Nov 19, 2026
“Self-pay pricing varies by dose. Patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg.”
Wegovy pen, NovoCare Pharmacy, read Nov 19, 2026
“Patients new to the Wegovy Savings Offer and Novocare home delivery pay $199 for each month of 0.25 mg and 0.5 mg. Offer is for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg and $399 per month for Wegovy HD (semaglutide) injection 7.2 mg.”
Pill or pen: Wegovy has both, Zepbound is injection only
Zepbound is a once-weekly injection, sold as a single-dose pen, a multi-dose KwikPen or a vial used with a syringe[6]. Wegovy comes as a once-weekly pen and, since its approval on December 22, 2025, as a once-daily pill[7],[12]. The pill is approved for adults; the pen is also approved for children aged 12 and older with obesity[7].
Cash prices differ by form: the Wegovy pill starts at $149 a month at NovoCare Pharmacy, checked November 19, 2026 and the Wegovy pen starts at $199 a month at NovoCare Pharmacy, an offer price (Offer is for 2 monthly fills through December 31, 2026; then $349 per month), checked November 19, 2026. For every GLP-1 pill and what it costs, see our GLP-1 pills guide.
Want a pill from Lilly instead? See Foundayo vs Zepbound, Lilly's once-daily pill set against Zepbound.
Insurance and Medicare coverage
Whether either medicine is covered depends on your plan and on what it is prescribed for. Some commercial plans cover them for weight management and many do not, and a plan that does may require prior authorization. The copay under a plan that covers them is set by that plan. For people whose commercial insurance covers them, each manufacturer prints a savings-card copay: "Single-Dose Pen 2.5 mg/0.5 mL (starting dosage) Insurance price: Pay as low as $25 per month for up to a 3-month prescription" for Zepbound (checked Nov 19, 2026) and "COMMERCIAL INSURANCE Pay as little as $25 per month*" for Wegovy (checked Nov 19, 2026). These are copays, not cash prices, and exclude government beneficiaries.
Medicare and Medicaid rules differ by medicine and by the condition it is prescribed for. See does Medicare cover Zepbound?, does Medicare cover Wegovy?, does Medicaid cover Zepbound? and Medicaid GLP-1 coverage by state. The GLP-1 insurance checker lists the questions to put to your insurer; the cash prices above are what you would pay if the answer is no.
Side effects and safety
The two labels list similar common side effects, mostly in the stomach and bowel. The most common on the Zepbound label (5% or more of patients) include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease[6]. On the Wegovy label they include nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence and gastroenteritis, among others[7]. In SURMOUNT-5 the most common adverse events on both were gastrointestinal, mostly mild to moderate, and happened mainly while the dose was being raised[1].
Both labels carry the same boxed warning about a risk of thyroid C-cell tumors[6],[7]. This page does not rank one medicine as safer. Your own history, other medicines and conditions decide what is suitable, so talk to a clinician before starting, switching or stopping either.
Source: FDA: Drug Safety Communication: FDA requires safety labeling changes for GLP-1 receptor agonists due to potential increased risk of rare but serious eye condition · United States · Published November 9, 2026
Zepbound or Wegovy: factors to discuss with a clinician
These are the differences on the record, not a recommendation. A clinician weighs them against your health history.
- Average weight loss. In the one head-to-head trial, average weight loss was larger on Zepbound[1].
- Pill or injection. Only Wegovy is available as a daily pill[7].
- Age. The Wegovy pen is approved from age 12 with obesity; Zepbound is approved for adults[7],[6].
- Other conditions. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity; Wegovy is also approved to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight[10],[11]. A medicine approved for a condition you have can also change what your insurance or Medicare covers.
- Cost and coverage. At the starting dose, Wegovy costs less than Zepbound. Cash prices rise with the dose, and coverage decides what you actually pay.
- Side effects. Both mainly cause gastrointestinal side effects, especially while the dose is being raised[1].
Compounded tirzepatide and semaglutide are not Zepbound or Wegovy
Compounded tirzepatide and compounded semaglutide are made by compounding pharmacies for an individual prescription and are not FDA approved: the FDA does not review compounded medicines for safety, effectiveness or quality before they are sold. They are different products from Zepbound and Wegovy, not cheaper copies of them, and none of the trial results on this page applies to them.
In our latest read, month to month, compounded tirzepatide costs $69 to $399 a month across 13 US online programs (checked November 19, 2026) and compounded semaglutide costs $39 to $299 a month across 12 programs (checked November 19, 2026). See what compounded tirzepatide costs and the cheapest semaglutide online for every row.
Source: FDA: Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) · United States · Decision February 21, 2025
Source: FDA: Federal Register notice — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B · United States · Published May 1, 2026
Related comparisons
- Ozempic vs Wegovy: two semaglutide brands, approved for different conditions.
- Semaglutide vs tirzepatide: the two active ingredients, across every brand and clinic.
- Brand-name GLP-1 prices: Zepbound, Wegovy, Ozempic and Foundayo cash prices by seller.
- US GLP-1 Price Index: every price we track, brand and compounded, with its history.
- Wegovy pill vs injection: the daily tablet against the weekly pen, with cash prices by seller.
- Mounjaro vs Zepbound: the same tirzepatide under two brands, approved for different uses.
Frequently asked questions
Is Zepbound more effective than Wegovy?
In the only head-to-head trial, yes on average. In SURMOUNT-5, published in the New England Journal of Medicine in 2025, adults with obesity and without type 2 diabetes lost an average of 20.2% of their body weight on Zepbound's active ingredient, tirzepatide, against 13.7% on Wegovy's, semaglutide, after 72 weeks. The trial was open-label and funded by Eli Lilly, which makes Zepbound. Averages are not predictions for one person, and results vary.
Is Zepbound cheaper than Wegovy?
No. At the starting dose, Wegovy costs less than Zepbound. Paying cash, Wegovy starts at $149 a month for the pill at NovoCare Pharmacy, checked November 19, 2026, and Zepbound at $299 a month for the KwikPen at LillyDirect, checked November 19, 2026. These are starting-dose medicine prices; higher doses cost more where the seller says so, and telehealth programs add a membership. With insurance, what you pay depends on your plan.
Will insurance cover Wegovy or Zepbound?
It depends on the plan. Some commercial plans cover them for weight management and many do not, and a plan that does may require prior authorization. Medicare and Medicaid rules differ by medicine and by the condition it is prescribed for. Check your plan's formulary; our Medicare and Medicaid guides set out the rules for each medicine.
Can I switch from Zepbound to Wegovy, or from Wegovy to Zepbound?
Switching is a prescriber's decision. The two have different active ingredients and different dose schedules, so a switch is not a like-for-like swap, and the dose to start on is set by your clinician. Ask your prescriber before changing or stopping either medicine.
Why do people stop Wegovy or Zepbound?
Common reasons are cost, insurance coverage and side effects. Both labels list stomach and bowel effects such as nausea, diarrhea, vomiting and constipation among the most common, and in SURMOUNT-5 these were mostly mild to moderate and happened mainly while the dose was being raised. If side effects or cost are a problem, talk to your prescriber before stopping.
Is the Wegovy pill as effective as the Zepbound injection?
No trial has compared them directly. In separate trials, the 25 mg Wegovy pill produced 13.6% average weight loss at 64 weeks (OASIS 4), and Zepbound produced up to 20.9% at its highest dose at 72 weeks (SURMOUNT-1). Different trials enrolled different people for different lengths of time, so those numbers cannot be compared head to head.
Which is safer, Wegovy or Zepbound?
Neither can be called safer from the evidence on this page. Both labels carry the same boxed warning about a risk of thyroid C-cell tumors, and both list mainly gastrointestinal side effects. Which medicine suits you depends on your own health history, and that is a decision to make with a clinician.
Are compounded tirzepatide and semaglutide the same as Zepbound and Wegovy?
No. Compounded tirzepatide and compounded semaglutide are made by compounding pharmacies and are not FDA approved; Zepbound and Wegovy are FDA approved brand-name medicines. They are different products. Compounded versions cost less in our latest read (tirzepatide $69 to $399 a month, semaglutide $39 to $299 a month, month to month, checked November 19, 2026).
Sources
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine 2025;393(1):26-36, published online May 11, 2025, PubMed 40353578. Open-label, 751 adults with obesity and without type 2 diabetes, maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks. Funded by Eli Lilly. Read November 5, 2026.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 2022;387:205-216, PubMed 35658024. Adults with obesity, or overweight with a weight-related complication, without diabetes; 72 weeks. Read November 5, 2026.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine 2021;384(11):989-1002, PubMed 33567185. Semaglutide 2.4 mg or placebo once weekly, 68 weeks. Funded by Novo Nordisk. Read November 5, 2026.
- Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine 2025;393(11):1077-1087, PubMed 40934115. 307 adults without diabetes, once daily, 64 weeks. Funded by Novo Nordisk. Read November 5, 2026.
- Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes & Endocrinology 2025;13(11):949-963, published online September 14, 2025, PubMed 40961952. 1,407 adults without diabetes, 72 weeks. Funded by Novo Nordisk. Read November 5, 2026.
- Zepbound (tirzepatide) injection, US prescribing information, revised August 2026, DailyMed. Read November 5, 2026.
- Wegovy (semaglutide) injection and Wegovy (semaglutide) tablets, US prescribing information, revised June 2026, DailyMed. Read November 5, 2026.
- Drugs@FDA, NDA 217806 (Zepbound, Eli Lilly): original approval November 8, 2023. Read November 5, 2026.
- Drugs@FDA, NDA 215256 (Wegovy injection, Novo Nordisk): original approval June 4, 2021. Read November 5, 2026.
- FDA news release, December 20, 2024: FDA Approves First Medication for Obstructive Sleep Apnea (Zepbound). Read November 5, 2026.
- FDA news release, March 8, 2024: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (Wegovy). Read November 5, 2026.
- AJMC, December 22, 2025: FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss (the Wegovy pill). Read November 5, 2026.
Prices come from the Peptide Clinic Finder US GLP-1 Price Index: each seller's own public price, read daily from a US connection, with every change kept in an archive. Manufacturer pages are linked plain; PCF has no commercial relationship with Eli Lilly or Novo Nordisk.